STAT Plus: Is Roche starting a price war in cancer? Maybe not
ADOBE
The company's decision to price its new pill at half the price of a competing drug will be an "interesting competitive dynamic to track," one analyst said.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario